Is the Prostate a Site of Endogenous DMT Synthesis? A Testable Hypothesis
Abstract
Endogenous N,N-dimethyltryptamine (DMT) has been detected in mammals, but its physiological functions and the distribution of functionally relevant synthesis remain unresolved. This paper proposes prostatic tissue as a candidate peripheral site of synthesis. Oncology studies document indolethylamine N-methyltransferase (INMT) expression in human prostate samples, including adjacent non-cancerous tissue, without establishing tryptamine synthesis there. It is hypothesised that prostatic tissue produces N,N-DMT and/or 5-methoxy-DMT (5-MeO-DMT), that production increases during specified conditions of pelvic autonomic activation, and that local tryptamine action modifies prostate-associated afferent signalling to the central nervous system. This model does not require transport of the molecule to the brain. The two analytes require separate biosynthetic and pharmacological assessment. The experimental programme separates tissue detection, demonstration of local biosynthesis, state
dependence, and causal neural effects. Targeted LC-MS/MS is the first screening step; positive detection alone would not establish synthesis. Negative results would constrain or disconfirm specified claims only under validated sampling and assay conditions. The proposal is a testable biochemical and neurophysiological hypothesis, not an established explanation of altered experience.
Related
- Evidence-Calibrated Reanalysis of an Otosclerosis Locus Generates a Testable Myeloid State Hypothesis
- A Testable Hypothesis of Frequency-Selective Electromagnetic Coupling in Sun–Planet Systems: Reinterpreting Wind–ARTEMIS Low-Frequency Spectral Overlaps
- The p38 MAPK/MSK1/NF-κB axis in chronic prostatitis/chronic pelvic pain syndrome: a testable hypothesis for innate immune inflammatory amplification
- A Testable Hypothesis and Research Protocol for the Original Proportions of the Great Sphinx of Giza
- The Convergence Hypothesis: A Testable Framework for Evaluating Potential Biosignatures on Mars and Ocean Worlds
BibTeX
@misc{green2026prostate,
title = {{Is the Prostate a Site of Endogenous DMT Synthesis? A Testable Hypothesis}},
author = {Shannon M. Green},
howpublished = {Zenodo},
year = {2026},
month = oct,
doi = {10.5281/zenodo.23534362},
url = {https://zenodo.org/records/23534362},
note = {CC BY 4.0},
}
RIS
TY - UNPB
TI - Is the Prostate a Site of Endogenous DMT Synthesis? A Testable Hypothesis
AU - Shannon M. Green
PY - 2026
DA - 2026/10/21
PB - Zenodo
DO - 10.5281/zenodo.23534362
UR - https://zenodo.org/records/23534362
AB - Endogenous N,N-dimethyltryptamine (DMT) has been detected in mammals, but its physiological functions and the distribution of functionally relevant synthesis remain unresolved. This paper proposes prostatic tissue as a candidate peripheral site of synthesis. Oncology studies document indolethylamine N-methyltransferase (INMT) expression in human prostate samples, including adjacent non-cancerous tissue, without establishing tryptamine synthesis there. It is hypothesised that prostatic tissue produces N,N-DMT and/or 5-methoxy-DMT (5-MeO-DMT), that production increases during specified conditions of pelvic autonomic activation, and that local tryptamine action modifies prostate-associated afferent signalling to the central nervous system. This model does not require transport of the molecule to the brain. The two analytes require separate biosynthetic and pharmacological assessment. The experimental programme separates tissue detection, demonstration of local biosynthesis, state dependence, and causal neural effects. Targeted LC-MS/MS is the first screening step; positive detection alone would not establish synthesis. Negative results would constrain or disconfirm specified claims only under validated sampling and assay conditions. The proposal is a testable biochemical and neurophysiological hypothesis, not an established explanation of altered experience.
ER -